The decision is more nuanced for intermediate-risk disease, with AS still an option for patients with favorable characteristics of their tumor as defined by the NCCN and involves serial DREs, prostate biopsies and PSA monitoring [50]. This evidence concerns the gene KLK3 and neoplasm.